IXICO plc Director/PDMR Shareholding (4442N)
09 August 2017 - 1:23AM
UK Regulatory
TIDMIXI
RNS Number : 4442N
IXICO plc
08 August 2017
8 August 2017
IXICO plc
("IXICO" or the "Company")
Share option grant
IXICO plc (AIM: IXI) ('IXICO' or the 'Company'), the digital
technologies company serving neuroscience, announces a grant of
options over the ordinary shares in the Company in accordance with
the rules of the Company's EMI Share Option Plan 2014 (the 'Plan')
exercisable at a price of 34p (being the closing middle market
price per ordinary share on 7 August 2017).
The award of options under the Plan is subject to certain
performance conditions and the options granted will vest upon the
achievement of strategic corporate goals in respect of
commercialisation of the Company's products and/or services or a
significant corporate development transaction occurring within
three years of the date of grant.
The total number of options being issued at this time is 713,940
and includes a grant of options to Susan Lowther, Chief Financial
Officer of the Company, as follows:
Name of Director Number of Total number Percentage
options of options held of issued share
granted capital under
option
------------------ ---------- ----------------- -----------------
Susan Lowther 235,000 545,196 2.01%
------------------ ---------- ----------------- -----------------
For further information please contact:
IXICO plc
Giulio Cerroni, Chief Executive Tel: +44 20 3763
Officer 7499
Susan Lowther, Chief Financial Officer
and Company Secretary
Shore Capital (Nomad and Broker) Tel: +44 20 7408
Bidhi Bhoma / Edward Mansfield /James 4090
Wolfe
FTI Consulting Limited (Investor Tel: +44 20 3727
Relations) 1000
Simon Conway/Mo Noonan
About IXICO
IXICO is the digital technologies company serving neuroscience.
Our mission is to transform the pursuit of improving brain health
through the application of digital technologies to neuroscience.
IXICO's specialist data analytics services are used by the global
pharmaceutical industry to select participants for clinical trials,
assess the safety and efficacy of new drugs in development and in
post marketing surveillance. Our neurological disease focus
includes Alzheimer's disease, Huntington's disease, Multiple
Sclerosis, Parkinson's disease and our integrated digital platform
encompasses the entire drug development lifecycle. It is a scalable
and secure infrastructure for the capture and analysis of
regulatory compliant clinical data to enable sponsors to make
rapid, better informed decisions. IXICO is also collaborating with
partners to develop new companion digital health products targeted
at improving patient outcomes.
More information is available on www.IXICO.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHEVLFBDVFLBBL
(END) Dow Jones Newswires
August 08, 2017 11:23 ET (15:23 GMT)
Ixico (LSE:IXI)
Historical Stock Chart
From Apr 2024 to May 2024
Ixico (LSE:IXI)
Historical Stock Chart
From May 2023 to May 2024